Clinical Trial

Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting

Study acronym: HYRISS
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
An international, multicenter, non-interventional, prospective, post-authorization, descriptive, non-PASS, study.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-11-21; most recent amendment 2026-01-09.
Status change: Recruiting → Active, Not Recruiting 2025-11-17
Status change: Not Yet Recruiting → Recruiting 2023-04-21
Trial Details
NCT Number NCT05633771
Lead Sponsor Sandoz
Conditions Inflammatory Bowel Disease
Enrollment 562 participants
Start Date 2023-02-16
Primary Completion 2025-12-15 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-12